Please use this identifier to cite or link to this item:
Title: Neurosteroidogenesis : a new pharmacological target for Tourette Syndrome?
Other Titles: A new pharmacological target for Tourette Syndrome?
Authors: Frau, Roberto
Keywords: Tourette syndrome -- Treatment
Finasteride -- Therapeutic use
Issue Date: 2016-12
Publisher: Malta Chamber of Scientists
Citation: Frau, R. (2016). Neurosteroidogenesis : a new pharmacological target for Tourette Syndrome? Xjenza, 4(2), 165-167.
Abstract: Tourette Syndrome (TS) is a childhood-onset neurological disorder characterised by multiple motor tics and one or more phonic tics. Number, frequency and tic complexity vary over time. Although clinical and epidemiological studies indicate that TS is a partially inherited disorder, its pathogenesis remains poorly understood (Singer, 2005). One of the main features of TS is that its prevalence in children is significantly higher than in adults; in most TS patients, tic severity follows a characteristic time course, with onset at 5-7 years of age, followed by an increase in frequency and intensity until the age 10 and 12 years, and a later remission phase after puberty (Leckman et al., 1998).
Appears in Collections:Xjenza, 2016, Volume 4, Issue 2
Xjenza, 2016, Volume 4, Issue 2

Files in This Item:
File Description SizeFormat 
Neurosteroidogenesis.pdf632.35 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.